Biotech 101: Valuing Binary Events
Sarepta Therapeutics, Revance Therapeutics, and Cytokinetics saw big moves recently; MannKind and Orexigen could be next.
This Week in Biotech: Is This the Return of Big M&A?
Merger and acquisition deals and rumors were the talk of the town this week, while three additional clinical and filing updates led to double-digit percentage moves.
Why GW Pharmaceuticals, Revance Therapeutics, and Allergan Are Today's 3 Best Stocks
M&A activity sends the S&P 500 decisively higher as GW Pharmaceuticals, Revance Therapeutics, and Allergan all jump by double digits.
Why Revance Therapeutics Inc. Shares Are Sitting Pretty
Revance shares are looking good after reporting positive phase 1/2 study data on RT002. Find out what investors should do based on this news.
Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Li
Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines
3 Stocks Near 52-Week Highs Worth Selling
Are these three stocks sells or belles? You be the judge!